GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 232 filers reported holding GENMAB A/S in Q4 2022. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,623 | -7.2% | 1,974 | 0.0% | 0.02% | 0.0% |
| Q2 2023 | $75,032 | -10.4% | 1,974 | -11.0% | 0.02% | -13.0% |
| Q1 2023 | $83,713 | -11.9% | 2,217 | -1.1% | 0.02% | -14.8% |
| Q4 2022 | $94,973 | -99.9% | 2,241 | -1.4% | 0.03% | 0.0% |
| Q3 2022 | $73,031,000 | -2.2% | 2,273 | -1.1% | 0.03% | +3.8% |
| Q2 2022 | $74,662,000 | -59.8% | 2,298 | -55.2% | 0.03% | -53.6% |
| Q1 2022 | $185,711,000 | -34.7% | 5,133 | -28.6% | 0.06% | -31.7% |
| Q4 2021 | $284,357,000 | -13.0% | 7,188 | -3.9% | 0.08% | -13.7% |
| Q3 2021 | $326,963,000 | +38.7% | 7,482 | +29.6% | 0.10% | +8.0% |
| Q2 2021 | $235,752,000 | +34.1% | 5,774 | +7.8% | 0.09% | +31.3% |
| Q1 2021 | $175,837,000 | +10.7% | 5,356 | +37.4% | 0.07% | 0.0% |
| Q4 2020 | $158,882,000 | +44.5% | 3,898 | +29.8% | 0.07% | +21.8% |
| Q3 2020 | $109,939,000 | +8.0% | 3,003 | 0.0% | 0.06% | -5.2% |
| Q2 2020 | $101,771,000 | – | 3,003 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |